阵发性睡眠性血红蛋白尿克隆在儿童重型再生障碍性贫血免疫抑制治疗中的意义

doi:10.7499/j.issn.1008-8830.2110109

摘要
图/表
参考文献(25)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (639 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的探究儿童重型再生障碍性贫血（severe aplastic anemia，SAA）中阵发性睡眠性血红蛋白尿（paroxysmal nocturnal hemoglobinuria，PNH）克隆与免疫抑制治疗（immunosuppressive therapy，IST）之间的关系。方法回顾性分析2012年1月至2020年5月收治且行IST的151例SAA患儿的临床资料，根据治疗前PNH克隆状态分为PNH克隆阴性组（135例）和PNH克隆阳性组（16例）。采用倾向性评分匹配控制混杂因素，分析PNH克隆对IST疗效的影响。结果 PNH克隆阳性患儿占10.6%（16/151），中位粒细胞克隆大小为1.8%。PNH克隆阳性组患儿初诊年龄偏大，初诊网织红细胞绝对值偏高（P<0.05）；倾向性评分匹配后，PNH克隆阴性组和PNH克隆阳性组患儿的基线特征差异均无统计学意义（P>0.05）。PNH克隆阳性组IST后6、12、24个月的总有效率均低于PNH克隆阴性组（P<0.05）。IST后PNH克隆演变存在一定异质性，伴PNH克隆者再生障碍性贫血-阵发性睡眠性血红蛋白尿综合征的3年累积发病率增加（P<0.05）。结论初诊时PNH克隆阳性的SAA患儿对IST的反应较差，且更易进展为再生障碍性贫血-阵发性睡眠性血红蛋白尿综合征。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李俊
	宗苏玉
	尹梓溪
	高洋洋
	刘立鹏
	万扬
	兰洋
	巩晓文
	竺晓凡

关键词 ：再生障碍性贫血, 阵发性睡眠性血红蛋白尿, 克隆演变, 免疫抑制治疗, 儿童

Abstract：Objective To study the association between paroxysmal nocturnal hemoglobinuria (PNH) clone and immunosuppressive therapy (IST) in children with severe aplastic anemia (SAA). Methods A retrospective analysis was performed on the medical data of 151 children with SAA who were admitted and received IST from January 2012 to May 2020. According to the status of PNH clone, these children were divided into a negative PNH clone group (n=135) and a positive PNH clone group (n=16). Propensity score matching was used to balance the confounding factors, and the impact of PNH clone on the therapeutic effect of IST was analyzed. Results The children with positive PNH clone accounted for 10.6% (16/151), and the median granulocyte clone size was 1.8%. The children with positive PNH clone had an older age and a higher reticulocyte count at diagnosis (P<0.05). After propensity score matching, there were no significant differences in baseline features between the negative PNH clone and positive PNH clone groups (P>0.05). The positive PNH clone group had a significantly lower overall response rate than the negative PNH clone group at 6, 12, and 24 months after IST (P<0.05). The evolution of PNH clone was heterogeneous after IST, and the children with PNH clone showed an increase in the 3-year cumulative incidence rate of aplastic anemia-PNH syndrome (P<0.05). Conclusions SAA children with positive PNH clone at diagnosis tend to have poor response to IST and are more likely to develop aplastic anemia-PNH syndrome.

Key words： Aplastic anemia Paroxysmal nocturnal hemoglobinuria Clonal evolution Immunosuppressive therapy Child

收稿日期: 2021-10-26

基金资助:国家重点研发项目（2016YFC0901503）。

通讯作者: 竺晓凡，女，主任医师。Email：xfzhu@ihcams.ac.cn。 E-mail: xfzhu@ihcams.ac.cn

作者简介: 李俊，男，硕士研究生，住院医；

引用本文:

李俊,宗苏玉,尹梓溪等. 阵发性睡眠性血红蛋白尿克隆在儿童重型再生障碍性贫血免疫抑制治疗中的意义[J]. 中国当代儿科杂志, 2022, 24(3): 303-308.

LI Jun,ZONG Su-Yu,YIN Zi-Xi et al. Significance of paroxysmal nocturnal hemoglobinuria clone in immunosuppressive therapy for children with severe aplastic anemia[J]. CJCP, 2022, 24(3): 303-308.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2110109 或 http://www.zgddek.com/CN/Y2022/V24/I3/303

	Luzzatto L, Risitano AM. Advances in understanding the pathogenesis of acquired aplastic anaemia[J]. Br J Haematol, 2018, 182(6): 758-776. PMID: 29974931. DOI: 10.1111/bjh.15443.
	Yoshida N, Kojima S. Updated guidelines for the treatment of acquired aplastic anemia in children[J]. Curr Oncol Rep, 2018, 20(9): 67. PMID: 29961134. DOI: 10.1007/s11912-018-0716-8.
	Narita A, Muramatsu H, Sekiya Y, et al. Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia[J]. Haematologica, 2015, 100(12): 1546-1552. PMID: 26315930. PMCID: PMC4666330. DOI: 10.3324/haematol.2015.132530.
	Gargiulo L, Zaimoku Y, Scappini B, et al. Glycosylphosphatidylinositol-specific T cells, IFN-γ-producing T cells, and pathogenesis of idiopathic aplastic anemia[J]. Blood, 2017, 129(3): 388-392. PMID: 27903525. DOI: 10.1182/blood-2016-09-740845.
	5 Fattizzo B, Dunlop A, Ireland RM, et al. Prognostic and predictive impact of small PNH clones in a large cohort of patients with myelodysplastic syndromes and aplastic anemia: a single-center experience[J]. Blood, 2018, 132(Suppl_1): 3870. DOI: 10.1182/blood-2018-99-116772.
	Kulagin A, Lisukov I, Ivanova M, et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study[J]. Br J Haematol, 2014, 164(4): 546-554. PMID: 24261566. DOI: 10.1111/bjh.12661.
	Najean Y, Haguenauer O. Long-term (5 to 20 years) evolution of nongrafted aplastic anemias. The Cooperative Group for the Study of Aplastic and Refractory Anemias[J]. Blood, 1990, 76(11): 2222-2228. PMID: 2257296. DOI: 10.1182/blood.V76.11.2222.2222.
	Narita A, Muramatsu H, Okuno Y, et al. Development of clinical paroxysmal nocturnal haemoglobinuria in children with aplastic anaemia[J]. Br J Haematol, 2017, 178(6): 954-958. PMID: 28643364. DOI: 10.1111/bjh.14790.
	9 中华医学会儿科学分会血液学组, 《中华儿科杂志》编辑委员会. 儿童获得性再生障碍性贫血诊疗建议[J]. 中华儿科杂志, 2014, 52(2): 103-106. DOI: 10.3760/cma.j.issn.0578-1310.2014.02.006.
	Lian Y, Shi J, Nie N, et al. Evolution patterns of paroxysmal nocturnal hemoglobinuria clone and clinical implications in acquired bone marrow failure[J]. Exp Hematol, 2019, 77: 41-50. PMID: 31472171. DOI: 10.1016/j.exphem.2019.08.005.
	de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories[J]. Blood, 2008, 112(8): 3099-3106. PMID: 18535202. DOI: 10.1182/blood-2008-01-133918.
	Ma XR, Wang J, Zhang WG, et al. Comparison of porcine anti-human lymphocyte globulin and rabbit anti-human thymocyte globulin in the treatment of severe aplastic anemia: a retrospective single-center study[J]. Eur J Haematol, 2016, 96(3): 260-268. PMID: 25966958. DOI: 10.1111/ejh.12584.
	Camitta BM. What is the definition of cure for aplastic anemia?[J]. Acta Haematol, 2000, 103(1): 16-18. PMID: 10705154. DOI: 10.1159/000040999.
	14 袁晓英, 王亚哲, 石韦华, 等. 流式检测PNH克隆的方法学探讨及临床筛检和意义[J]. 中国生物工程杂志, 2019, 39(9): 33-40. DOI: 10.13523/j.cb.20190905.
	Tu JK, Pan H, Li RN, et al. PNH clones for aplastic anemia with immunosuppressive therapy: a systematic review and meta-analysis[J]. Acta Haematol, 2021, 144(1): 34-43. PMID: 32877903. DOI: 10.1159/000506387.
	Wang B, He B, Zhu YD, et al. The predictive value of pre-treatment paroxysmal nocturnal hemoglobinuria clone on response to immunosuppressive therapy in patients with aplastic anemia: a meta-analysis[J]. Hematology, 2020, 25(1): 464-472. PMID: 33269994. DOI: 10.1080/16078454.2020.1848083.
	Yoshida N, Yagasaki H, Takahashi Y, et al. Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia[J]. Br J Haematol, 2008, 142(3): 427-435. PMID: 18537977. DOI: 10.1111/j.1365-2141.2008.07182.x.
	Timeus F, Crescenzio N, Lorenzati A, et al. Paroxysmal nocturnal haemoglobinuria clones in children with acquired aplastic anaemia: a prospective single centre study[J]. Br J Haematol, 2010, 150(4): 483-485. PMID: 20456361. DOI: 10.1111/j.1365-2141.2010.08219.x.
	Mon Père N, Lenaerts T, Pacheco JM, et al. Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria[J]. PLoS Comput Biol, 2018, 14(6): e1006133. PMID: 29912864. PMCID: PMC6023248. DOI: 10.1371/journal.pcbi.1006133.
	Dingli D, Luzzatto L, Pacheco JM. Neutral evolution in paroxysmal nocturnal hemoglobinuria[J]. Proc Natl Acad Sci U S A, 2008, 105(47): 18496-18500. PMID: 19011109. PMCID: PMC2587638. DOI: 10.1073/pnas.0802749105.
	Scheinberg P, Marte M, Nunez O, et al. Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine[J]. Haematologica, 2010, 95(7): 1075-1080. PMID: 20595102. PMCID: PMC2895030. DOI: 10.3324/haematol.2009.017889.
	Bat T, Abdelhamid ON, Balasubramanian SK, et al. The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy[J]. Br J Haematol, 2018, 182(5): 730-733. PMID: 28804905. PMCID: PMC5812827. DOI: 10.1111/bjh.14862.
	Yenerel MN, Muus P, Wilson A, et al. Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status[J]. Blood Cells Mol Dis, 2017, 65: 29-34. PMID: 28437723. DOI: 10.1016/j.bcmd.2017.03.013.
	Socié G, Schrezenmeier H, Muus P, et al. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry[J]. Intern Med J, 2016, 46(9): 1044-1053. PMID: 27305361. DOI: 10.1111/imj.13160.
	Lee JW, Peffault de Latour R, Brodsky RA, et al. Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry[J]. Am J Hematol, 2019, 94(1): E37-E41. PMID: 30370949. DOI: 10.1002/ajh.25334.